Janssen's IV Simponi wins FDA nod for rheumatoid arthritis

07/19/2013 | Medscape (free registration)

Janssen Biotech obtained the FDA's approval to market an intravenous formulation of Simponi Aria, or golimumab, in combination with methotrexate as a therapy for moderately to severely active rheumatoid arthritis. The drug, a tumor necrosis factor inhibitor, already was cleared for subcutaneous administration. The approval was based on data from a 592-patient, late-stage trial.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN